The present results also show that QSYQ can act on CHD by different targets of RAAS, especially renin and Ang II, ACE/ACE2, and AT1/AT2, eventually decreasing the levels of the MMP-9 and TGF-β, which can treat CHD efficiently and safely. The gene discussed is AGTR1; the disease is coronary artery disorder.